熱門資訊> 正文
由于前景下调，特许权使用费交易，Ascendis股价下跌12%
2024-09-04 23:06
- Shares of Ascendis (ASND) fell 12% in morning trading Wednesday, the day after the Danish drug developer lowered its revenue outlook and announced it had entered into a royalty funding deal with Royalty Pharma for U.S. sales of its drug Yorvipath.
- Ascendis (ASND) released its Q2 earnings report after market close on Tuesday and revised its 2024 revenue outlook for its drug Skytrofa to EUR 220M to EUR 240M.
- The company added that pending the launch timing of Yorvipath in the U.S., it expects to be operating cash flow breakeven on a quarterly basis in 2024 or 2025, according to its Q2 earnings release.
- In May, Ascendis (ASND) forecasted 2024 Skytrofa revenue of EUR 320M to EUR 340M.
- Also late Tuesday, Ascendis (ASND) said it has entered into a deal with Royalty Pharma for its hormone replacement therapy Yorvipath. Under the deal, Ascendis (ASND) will receive $150M upfront in exchange for a 3% royalty on U.S. net sales.
More on Ascendis Pharma
- Ascendis Pharma A/S (ASND) Q2 2024 Earnings Call Transcript
- Ascendis Pharma: Yorvipath Approved, Launch Delayed, Many Other Updates Coming Up
- Weaker USD, Revenue Growth, And TransCon Technology Make Ascendis Pharma A Strong Buy Opportunity
- Ascendis Pharma GAAP EPS of -€1.91, revenue of €36M; revises FY24 revenue outlook
- Ascendis and Royalty Pharma enter into $150M royalty funding agreement
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
